期刊文献+

ⅠB~ⅡB期前宫颈癌髂总淋巴结转移的临床分析 被引量:8

Iliac lymph node metastasis in patients with stage ⅠB~ⅡB cervical carcinoma
下载PDF
导出
摘要 目的:探讨ⅠB~ⅡB期宫颈癌髂总淋巴结转移的危险因素及其治疗。方法:回顾性分析首次确诊并行手术治疗的652例ⅠB~ⅡB期宫颈癌患者的临床病理资料及45例髂总淋巴结阳性宫颈癌的治疗结果。结果:652例宫颈癌患者中,45例(6.90%)发生髂总淋巴结转移。单因素分析显示,临床期别、盆腔淋巴结阳性组数(除髂总淋巴结外)、肌层浸润、脉管瘤栓与髂总淋巴结转移有关,但lonistic回归法分析结果显示,宫颈癌髂总淋巴结转移的独立危险因素为临床期别、盆腔淋巴结阳性组数(除髂总淋巴结外)。结论:临床期别、盆腔淋巴阳性组数(除髂总淋巴结外)为宫颈癌髂总淋巴结转移的独立危险因素。髂总淋巴结阳性宫颈癌的治疗值得进一步探讨。 OBJECTIVE:To study the risk factors for common iliac lymph node metastasis in patients with cervical carcinoma in stage ⅠB-ⅡB and the treatment in patients with positive common iliac lymph node. METHODS: The pathological and clinical features and treatment of cervical carcinoma patients were retrospectively reviewed and analyzed. RESULTS:Of the 652 cases reviewed, 45 (6.90%) had positive common iliac lymph node. Single factor analysis showed that clinical stage, number of pelvic lymph node metastasis group (excluding common iliac lymph node), deep cervical stromal invation, lymph-vascular space invasion were associated with common iliac lymph node metastasis. Factors predictive of common iliac lymph node metastasis on logistic forward regression were clinical stage and number of pelvic lymph node metastasis group (excluding common iliac lymph node). CONCLUSIONS: Clinical stage and Number of pelvic lymph node metastasis group (excluding common iliac lymph node) are the independent predictive factors for common iliac lymph metastasis of cervical carcinoma. The treatment of cervical carcinoma patients with positive common iliac lymph node is worth of further study.
出处 《中华肿瘤防治杂志》 CAS 2007年第14期1097-1099,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 存活率 宫颈肿瘤/病理学 淋巴转移 危险因素 survival tate cervix neoplasms/pathology lymphatic metastasis risk factors
  • 相关文献

参考文献8

  • 1Monk B J,Cha D S,Walker J L,et al.Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage ⅠB and IA cervical carcinoma[J].Gynecol Onco1,1994,54 (1):4-9.
  • 2Sakuragi N,Satoh C,Takeda N,et al.Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages ⅠB,ⅡA,and ⅡB cervical carcinoma treated with radical hysterectomy[J].Cancer,1999,85 (7):1547-1554.
  • 3Aoki Y,Sasaki M,Watanabe M,et al.High-risk group in node-positive patients with stage ⅠB,ⅡA,and ⅡB cervical carcinoma after radicalhysterectomy and postoperative pelvic irradiation[J].Gynecol Oncol,2000,77:305-309.
  • 4Aoki Y,Sasaki M,Watanabe M,et al.High-risk group in node-positive patients with stage ⅠB,ⅡA,and ⅡB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation[J].Gynecol Oncol,2000,77(2):305-309.
  • 5Takeshi Kodaira,MD,Nobukazu Fuwa,MD,et al.Long-Term Clinical Outcomes of Postoperative Pelvic Radiotherapy With or Without Prophylactic Paraaortic Irradiation for Stage Ⅰ-Ⅱ Cervical Carcinoma With Positive Lymph Nodes[J].Am J Clinic Oncol,2004,27(2):140-148.
  • 6Ryu H S,Chun M,Chang K H,et al.Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-isk early stage cervical cancer patients[J].Gynecol Oncol,2005,96(2):490-49512.
  • 7Peters W A,Liu P Y,harrett R J,et al.Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high risk early stage cancer of the cervix[J].J Clin Oncol,2000,18(8):1606-1610.
  • 8宋红林,唐步坚.放化疗联合疗法在中晚期宫颈癌治疗中的应用分析[J].肿瘤防治杂志,2004,11(6):641-642. 被引量:12

二级参考文献9

  • 1曹泽毅.中华妇产科学[M].北京:人民卫生出版社,1999.2129.
  • 2World Health Organization. WHO handbook for reporting results of cancer treatment, WHO Publication 48 Geneva, Switzerland[J]. World Health Organization, 1979,48(7): 14- 21.
  • 3Sardi J E, Giaroli A, Sananes C, et al. Long-term follow up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results[J].Gynecol Oncol, 1997,67 (1): 61 - 69.
  • 4Zanetta G, Lissoni A, Gabriele A, et al. Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinona[J]. Gynecol Oncol, 1997,64(3) :431-435.
  • 5Whitney C W, Sause W, Bundy B N, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage Ⅱ B-ⅣA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study[J]. J Clin Oncol,1999,17(5): 1339-1348.
  • 6Richmond R C. Toxic variability and radiation sensitization by dichlorodiammineplatinum (Ⅱ) complexes in Salmonella typhimurium cells[J]. Radiat Res, 1984, 99(3):596-608.
  • 7Wallner K E, Li G C. Effect of cisplatin resistance on cellular radiation response[J]. Int J Radiat Oncol Biol Phy, 1987,13 (4):587-591.
  • 8Rose P G, Bundy B N, Watkins E B,et al. Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer[J]. N EnglJ Med,1999,340(15):1144-1153.
  • 9Peters W A, Lin P Y, Barrett R J, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of cervix[J]. J Clin Oncol, 2000,18(8):1606-1613.

共引文献11

同被引文献74

引证文献8

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部